Charlotte Lanièce Delaunay

Charlotte Lanièce Delaunay

Auto-generated profile, based on publicly available information

Charlotte Lanièce Delaunay

Epiconcept Epidemiology Department Paris

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FSFabien Subtil
Fabien Subtil
CDCharlotte Delaunay
Charlotte Delaunay
AKAlpha Keita
Alpha Keita
MSMamadou Saliou Sow
Mamadou Saliou Sow
ATAbdoulaye Touré
Abdoulaye Touré
JEJean-François Etard
Jean-François Etard
This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors participating in the Postebogui study in Guinea. The median time of reverse-transcription polymerase chain reaction negativity was 46.4 days after symptom onset (95% confidence interval, 11–82.6). The results emphasize the importance of the World Health Organization recommendations for survivors’ management.

1 November 2020 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
CDCharlotte Lanièce Delaunay
Charlotte Lanièce Delaunay
SSSahar Saeed
Sahar Saeed
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen

21 May 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
CDCharlotte Laniece Delaunay
Charlotte Laniece Delaunay
NVNuno Verdasca
Nuno Verdasca
SMSusana Monge
Susana Monge
LDLisa Domegan
Lisa Domegan
NSNoémie Sève
Noémie Sève
EGEuropean primary care VE group
European primary care VE group
We estimated the effectiveness of 2024/25 COVID‐19 vaccination against medically attended SARS‐CoV‐2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test‐negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34–85) overall, 73% (95% CI: 21–94) and 54% (95% CI: −3 to 83) in the first and second months post‐vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33–86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID‐19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.

10 November 2024 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
LMLore Merdrignac
Lore Merdrignac
CDCharlotte Laniece Delaunay
Charlotte Laniece Delaunay
NVNuno Verdasca
Nuno Verdasca
LVLorena Vega‐Piris
Lorena Vega‐Piris
JOJoan O'DOnnell
Joan O'DOnnell
TGthe VEBIS Primary Care Vaccine Effectiveness Group
the VEBIS Primary Care Vaccine Effectiveness Group
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.

28 March 2024 in Eurosurveillance
Verified
Journal Article
Open access
CDCharlotte Lanièce Delaunay
Charlotte Lanièce Delaunay
IMIván Martínez-Baz
Iván Martínez-Baz
NSNoémie Sève
Noémie Sève
LDLisa Domegan
Lisa Domegan
CMClara Mazagatos
Clara Mazagatos
OGon behalf of the European Primary Care Vaccine Effectiveness Group
on behalf of the European Primary Care Vaccine Effectiveness Group
Background: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. Results: Among adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%) < 90, 90–179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32–51%) overall and 56% (95% CI: 47–64%), 22% (95% CI: 2–38%) and 3% (95% CI: −78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification. Conclusion: Primary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.

7 April 2023 in International Journal of Drug Policy
Verified
Journal Article
Open access
CDCharlotte Lanièce Delaunay
Charlotte Lanièce Delaunay
MKMarina B. Klein
Marina B. Klein
AGArnaud Godin
Arnaud Godin
JCJoseph Cox
Joseph Cox
NKNadine Kronfli
Nadine Kronfli
MMMathieu Maheu-Giroux
Mathieu Maheu-Giroux
In Montreal (Canada), high hepatitis C virus (HCV) seroincidence (21 per 100 person-years in 2017) persists among people who have injected drugs (PWID) despite relatively high testing rates and coverage of needle and syringe programs (NSP) and opioid agonist therapy (OAT). We assessed the potential of interventions to achieve HCV elimination (80% incidence reduction and 65% reduction in HCV-related mortality between 2015 and 2030) in the context of COVID-19 disruptions among all PWID and PWID living with HIV. Using a dynamic model of HCV-HIV co-transmission, we simulated increases in NSP (from 82% to 95%) and OAT (from 33% to 40%) coverage, HCV testing (every 6 months), or treatment rate (100 per 100 person-years) starting in 2022 among all PWID and PWID living with HIV. We also modeled treatment scale-up among active PWID only (i.e., people who report injecting in the past six months). We reduced intervention levels in 2020–2021 due to COVID-19-related disruptions. Outcomes included HCV incidence, prevalence, and mortality, and proportions of averted chronic HCV infections and deaths. COVID-19-related disruptions could have caused temporary rebounds in HCV transmission. Further increasing NSP/OAT or HCV testing had little impact on incidence. Scaling-up treatment among all PWID achieved incidence and mortality targets among all PWID and PWID living with HIV. Focusing treatment on active PWID could achieve elimination, yet fewer projected deaths were averted (36% versus 48%). HCV treatment scale-up among all PWID will be required to eliminate HCV in high-incidence and prevalence settings. Achieving elimination by 2030 will entail concerted efforts to restore and enhance pre-pandemic levels of HCV prevention and care.